



Financial Tear Sheet


Corporate Profile

Tokai Pharmaceuticals is a biopharmaceutical company previously focused on developing and commercializing innovative therapies for prostate cancer and other hormonally driven diseases. The ARMOR2 and ARMOR3-SV clinical trials of Tokai's drug candidate, galeterone, for the treatment of metastatic castration-resistant prostate cancer (mCRPC) have been closed, with only patients in ARMOR2 long-term extension continuing treatment at this time. Plans remain in effect to present data from the ARMOR3-SV trial in a scientific forum once fully available and analyzed. Assessment of plans for galeterone, the ARDA platform and Tokai's AR-V7 assay work are underway at this time.

Stock Information

TKAI (Common Stock)

Exchange NASDAQ (US Dollar)
Price **\$0.00**
Change (%) 0.00 (NaN%)
Volume 0
52 Week Low \$0.00
Market Cap \$13,802,350
Rolling EPS 0.00
PE Ratio 0
Shares Outstanding 22,641,651
Data as of 05/10/17 4:00 p.m. ET



Recent Press Releases & Upcoming Events

12/22/16

Tokai Pharmaceuticals and Otic Pharma Enter into Share Purchase Agreement

09/08/16

Tokai Pharmaceuticals Announces Review of Strategic Alternatives

07/29/16

Tokai Pharmaceuticals Announces Reduction in Force

There are currently no events scheduled.

SEC Filings

Filing Date	Form
09/29/17	8-K
09/26/17	CT ORDER
08/22/17	8-K
08/21/17	424B5

Data provided by Nasdaq. Minimum 15 minutes delayed.